DRMA
Dermata Therapeutics, Inc.
Next earnings Aug 11, 2026 · consensus $-0.56 EPS
Last earnings -4.0% on 2026-05-13
$1.30
▲ +0.78%$1.30▼ -79.37%
over 1Y
L $1.14EODHDH $7.30
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+0.8%
1W+5.7%
1M-3.0%
3M+14.0%
YTD-40.4%
1Y-79.4%
Hold
Conviction
Horizon
Medium (3–12mo)
Street · 7 analysts
Buy
Conservative balance sheet (liabilities/equity 0.26x).
Return on equity -121.5% · latest
Dermata Therapeutics, Inc. shows limited reported revenue, and -121.5% ROE.
Supporting the case: conservative balance sheet (liabilities/equity 0.26x).
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$7.86M | -$9.67M | -$8.04M | -$12.5M | -$7.77M |
| Net income | -$7.90M | -$9.61M | -$7.79M | -$12.3M | -$7.56M |
| Diluted EPS | — | — | -$39.99 | -$80.32 | -$8.16 |
| Net margin | — | — | — | — | — |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value-$2.33M
EV / EBITDA—
EV / Sales—
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-145.7%
FCF yield—
Quality & risk
ROIC (est.)-98.7%
Free cash flow—
Total debt$0.00
Net cash$7.52M
Piotroski F-Score3/6
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY-25.9%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsSome governance/structural items recently, but no outright red flags.
- 8-K Officer / director change2026-05-27
- S-3/A Shelf registration (potential raise)2026-05-22
- 8-K Earnings results2026-05-13
- 10-Q Quarterly report2026-05-13
- DEF 14A Proxy statement2026-04-17
- 8-K Earnings results2026-03-26
- 10-K Annual report2026-03-26
- 8-K Officer / director change2026-02-25
- 8-K Auditor change2026-02-03
Recent filings
all on EDGAR ↗4Period ending 2026-06-162026-06-16open ↗S-8Filing2026-06-04open ↗SCHEDULE 13DFiling2026-06-01open ↗EFFECTFiling2026-05-29open ↗424B3Filing2026-05-29open ↗8-KPeriod ending 2026-05-272026-05-27open ↗S-3/AFiling2026-05-22open ↗SCHEDULE 13G/AFiling2026-05-13open ↗10-QPeriod ending 2026-03-312026-05-13open ↗8-KPeriod ending 2026-03-312026-05-13open ↗SCHEDULE 13G/AFiling2026-04-22open ↗ARSPeriod ending 2025-12-312026-04-17open ↗
Frequently asked
- Is Dermata Therapeutics, Inc. (DRMA) a buy?
- DRMA currently carries a Hold rating with 2/5 conviction, derived from its latest SEC filings. Conservative balance sheet (liabilities/equity 0.26x).
- What is Dermata Therapeutics, Inc.'s quality score?
- DRMA scores 52.88209126145173/100 (grade C-) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001853816, latest 10-Q filed 2026-05-13) · EODHD · as of 7/1/2026, 4:51:30 AM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.